Cambridge Cognition win £1.1 million eCOA contract for rare blood disease trial

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a £1.1m contract with a major pharmaceutical company to provide electronic clinical outcome assessments (“eCOA”) and hardware for a rare blood disease study running over the next two years. The new contract, with an existing customer, is for a mixture of eCOA licenses, services and hardware to support an upcoming clinical trial.

As a leader in digital outcome assessments, Cambridge Cognition primarily provides cognitive measures and eCOA solutions for clinical trials in central nervous systems disorders. Impressed by Cambridge Cognition’s expertise and performance in handling multi-site-multi-language studies, the customer has selected the Company to be the eCOA provider for this trial. This recognition is important for the Company as the provision of eCOA for clinical trials is a sizeable growth market, valued at over US$1bn per annum and growing at more than 15% according to market research1

Cambridge Cognition has been contracted to provide the platform and the hardware for capturing participants’ experiences as well as their responses to standardised questionnaires and scales. Cambridge Cognition’s experienced clinical project management team will work closely with the customer to ensure successful use of the software and devices. 

Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition, said: 

“Cambridge Cognition has a strong history of delivering cognitive assessments in the field, traditionally in clinics and now also at home. We are pleased to see this new order from an existing client, our reputation for quality, service and scientific rigour is enabling us to win eCOA-only clinical trials.”

References

1.     GrandView Research 2018 eCOA Report

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition 25% growth in revenues to £12.6 million

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a trading update for the year ended 31 December 2022. Unaudited highlights for the year ended 31 December 2022 ·         Revenue ahead of

Cambridge Cognition Holdings

Cambridge Cognition acquires Winterlight Labs Inc

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the acquisition of Winterlight Labs Inc, a leader in monitoring cognitive impairment through free-speech analysis.  The total consideration for the Acquisition is

Cambridge Cognition Holdings

Cambridge Cognition plc investor live webinar today

The interim results for the six months ended 30 June 2022 were released earlier today on 20 September 2022. The Company will conduct a live presentation and Q&A session for investors later today at 5:30 pm BST. The presentation

Cambridge Cognition Holdings

Cambridge Cognition growth in revenue of 31%

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced its unaudited interim results for the six months ended 30 June 2022. The Company followed its strong performance in 2021 with a 31%

Cambridge Cognition Holdings

Cambridge Cognition partnering with the University of Oxford

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it will be collaborating with the University of Oxford by providing cognitive assessments for the Impact of Semaglutide in Amyloid

Cambridge Cognition Holdings

Cambridge Cognition signs two PTSD trial agreements

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced two agreements in a new therapeutic area for the Company, post-traumatic stress disorder.  Most recently, a research agreement was entered into

Cambridge Cognition Holdings

Cambridge Cognition directors buy shares in company

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, announced today that it was informed on the 21st July 2022 of the following purchases of the Company’s ordinary shares by Directors and PDMRs of the

Cambridge Cognition Holdings

Cambridge Cognition to announce preliminary results on 12 April 2022

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, will announce its preliminary results for the year ended 31 December 2021 on 12 April 2022. Cambridge Cognition is a technology company developing digital

No more posts to show